Novartis/Sandoz make history with 1st US biosimilar Zarxio
Novartis and its Sandoz unit made history on 6 March, gaining the first approval of a biosimilar in the US – Zarxio (filgrastim-sndz).
Novartis and its Sandoz unit made history on 6 March, gaining the first approval of a biosimilar in the US – Zarxio (filgrastim-sndz).